LIFECORE BIOMEDICAL, INC. Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized
LIFECORE BIOMEDICAL, INC. (LFCR) reported Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized of $5.30 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized · last filed 2026-08-05
- LIFECORE BIOMEDICAL, INC. contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized for the quarter ending 2026-03-31 was $3.11M.
- LIFECORE BIOMEDICAL, INC. contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized for the quarter ending 2025-09-30 was $412.00K.
- LIFECORE BIOMEDICAL, INC. contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized for fiscal 2025 was $2.11M.
| Period end | Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized 3 month | Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized 6 month | Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized 7 month | Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized 9 month | Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $5.30M 10-Q · filed 2026-08-05 | ||||
| 2026-03-31 | $3.11M 10-Q · filed 2026-05-06 | ||||
| 2025-12-31 | $921.00K 10-KT · filed 2026-03-16 | ||||
| 2025-09-30 | $412.00K 10-Q · filed 2025-11-06 | ||||
| 2025-05-25 | $2.11M 10-KT · filed 2026-03-16 | ||||
| 2025-02-23 | $2.11M 10-Q · filed 2025-04-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |